Cargando…
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
BACKGROUND: The BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment. METHODS: Patients received standa...
Autores principales: | Cornish, Elisa E, Teo, Kelvin YC, Gillies, Mark C, Lim, Lyndell L, Nguyen, Vuong, Wickremasinghe, Sanjeewa, Mehta, Hemal, McAllister, Ian L, Fraser-Bell, Samantha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763198/ https://www.ncbi.nlm.nih.gov/pubmed/34340975 http://dx.doi.org/10.1136/bjophthalmol-2021-319839 |
Ejemplares similares
-
A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study
por: O’Day, Roderick, et al.
Publicado: (2020) -
12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021) -
Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023) -
Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022) -
Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023)